netFormulary Tameside and Glossop Integrated Care NHS
NHS Foundation Trust  

Useful Links

News Feed

MHRA Drug Safety Update (June 2019): DOACs, GLP-1 receptor agonists, Oral retinoids.

MHRA Drug Safety Update (May 2019): Alemtuzumab, tofacitinib, magnesium sulfate

MHRA Drug Safety Update (April 2019): Valproate, belimumab, pregabalin, gabapentin, elvitegravir boosted with cobicistat

MHRA Drug Safety Update (March 2019): fluoroquinolone antibiotics

MHRA Drug Safety Alert (February 2019): Carbimazole, SGLT2 inhibitors

MHRA Drug Safety Update (January 2019): Tapentidol, Ipilimumab

>>> more news


This Formulary is intended primarily for use by staff working within Tameside and Glossop Integrated Care NHS Foundation Trust . It is also accessible by General Practitioners , patients and the public at

Tameside and Glossop Integrated Care NHS Foundation Trust Formulary

The on-going development of the formulary is overseen by the Integrated Medicines Optimisation Group (IMOG) and choices are based on clinical evidence and consultant and GP opinion. The formulary aims to provide information on medicines available at the trust reflecting evidence-based, cost-effective choices and whether their use is considered as good use of NHS resources.

Applications for medicines to be considered for inclusion in the trust formulary must be submitted to the Integrated Medicines Optimisation Group (IMOG).

The application form to submit an application is available at:

New Medicines Application Form 

New Medicines Application Form (NICE APPROVED)

The database is formatted in accordance with British National Formulary chapter classification for ease of use and also includes hyperlinks to the e-BNF, e-BNFc and to the electronic medicines compendium which is a library of Summaries of Product Characteristics (SPCs) and Patient Information Leaflets (PILs).

The formulary will assume that prescribers will use a  drug’s summary of product characteristics (SPC) and the British National Formulary (BNF) to inform decisions made with individual patients (this includes obtaining information on special warnings, precautions for use, contraindications and adverse effects of pharmacological treatments). The formulary should be used in conjunction with clinical judgement and decision-making appropriate for the individual patient.

The formulary recommends some drugs for indications for which they do not have UK marketing authorisation at the date of publication, if there is good evidence to support that use. The prescriber should follow the relevant professional guidance, taking full responsibility for the decision.

Formulary approved medicines are displayed in order of preference and first and second line choices for groups of medicines are indicated if applicable. Where there is no order of preference, medicines appear in alphabetical order. Those medicines which are restricted (by speciality , consultant, indication or clinical area) are also highlighted within the formulary. Although the formulary reflects medicines currently in use at TGH, any medicine approved for use by the National Institute for Health and Care Excellence (NICE) will automatically be approved for use in the Trust if an application to use it is received.

Hyperlinks to relevant National Guidance, such as Drug Safety Updates and guidance issued by NICE, are also included within each section of the formulary. Links to Local Trust Guidelines are also included, however these are presently only available if viewing the formulary on the Trust Intranet. Copies of local guidelines are available on request by using the 'Feedback' link at the top of the page.

NICE information is also available at:

National Institute for Health and Care Excellence

Searches of the formulary can be undertaken by medicine name, class or medical condition. Some medicines may appear more than once within the formulary. If they are within the same section, this may be because there is more than one brand of the medicine available. However, medicines may also appear in more than one section, as they may be used for more than one medical condition.Some medicines are approved only for prescribing by the hospital, whereas the prescribing for others can be initiated or maintained by local General Practitioners (GPs). A traffic light system highlights these medicines within the formulary.

The Integrated Medicines OPtimisation Group (IMOG) would be pleased to receive constructive comments on any aspect of the formulary, which can be made by using the 'Feedback' link at the top of the page.

Brendan Ryan, Medical Director, Chair, IMOG

Jonathan Peacock, Chief Pharmacist

Xin Wei Tan, Formulary Pharmacist

Updated April 2020

   Last updated: 01/12/2020 14:58:51.